Investigation questions FDA approval of Aduhelm
US Congress investigators level sharp criticism at health authorities’ approval process of Biogen’s medical treatment of Alzheimers.
by marketwire, translated by kristoffer grønbæk
The US Food and Drug Administration’s approval process of Biogen’s candidate for medical treatment of Alzheimers was “rife with irregularities,” providing grounds for serious concern as to how the approval came about, state congressional investigators noted Thursday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA gives new Biogen Alzheimer's treatment priority status
For subscribers
